ArticleMedicine2025
Cytomegalovirus reactivation in autoimmune liver diseases. Can we diagnose it earlier?: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potentially fatal hemorrhagic duodenal ulcers caused by cytomegalovirus infection complicating autoimmune hepatitis with acute liver failure, successfully treated with multiple interventional radiology procedures.Clinical journal of gastroenterology · 2026Article
- Cytomegalovirus Hepatitis Occurring in a Young Patient With Autoimmune Polyglandular Syndrome and Pediatric-Onset Autoimmune Hepatitis.ACG case reports journal · 2026Article
- HCMV infection disrupts barrier functions and promotes epithelial-mesenchymal transition in a cholangiocyte organoid model.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleClinical evidence showing that biliary inflammation predisposes individuals to cytomegalovirus (CMV) disease has been growing, and some studies even indicate that this risk may surpass that associated with immunosuppression alone. Autoimmune hepatitis (AIH) can be challenging to manage and often necessitates lifelong use of immunosuppressive regimens. Additionally, AIH can be associated with chronic biliary diseases in conditions known as overlap syndromes. In one such syndrome, AIH is associated with primary sclerosing cholangitis, a well-established cause of chronic biliary inflammation that results in ductal destruction and fibrosis, thus combining 2 significant risk factors for CMV disease. PATIENT CONCERNS: We report a case of a young woman with AIH and primary sclerosing cholangitis since her childhood. She was taking prednisone, azathioprine, and tacrolimus and experienced jaundice. Azathioprine and tacrolimus serum levels were adequate and AIH was well controlled, whereas total bilirubin, alkaline phosphatase, and gamma-glutamyl transferase were elevated. After the virus reactivation, the patient has been concerned about the immunosuppressive drugs she has been taken. DIAGNOSES: CMV reactivation was diagnosed only after hospital admission when serum polymerase chain reaction was 3153 copies/mL.
interventionIntravenous ganciclovir resulted in rapid improvement. OUTCOMES: The patient achieved full recovery and no further hospitalization was needed. LESSONS: Patients with similar conditions need careful vigilance for biliary CMV reactivation. Even if polymerase chain reaction is not available, CMV serology should be performed as soon as the symptoms are detected, avoiding delays in diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.